1808 related articles for article (PubMed ID: 26995305)
21. Cyclin-Dependent Kinase 4/6 Inhibitors for the Treatment of Breast Cancer: A Review of Preclinical and Clinical Data.
Vidula N; Rugo HS
Clin Breast Cancer; 2016 Feb; 16(1):8-17. PubMed ID: 26303211
[TBL] [Abstract][Full Text] [Related]
22. CDK4/6 Inhibition as a therapeutic strategy in breast cancer: palbociclib, ribociclib, and abemaciclib.
Laderian B; Fojo T
Semin Oncol; 2017 Dec; 44(6):395-403. PubMed ID: 29935901
[TBL] [Abstract][Full Text] [Related]
23. Cyclin-Dependent Kinase 4 and 6 Inhibitors in Cell Cycle Dysregulation for Breast Cancer Treatment.
Susanti NMP; Tjahjono DH
Molecules; 2021 Jul; 26(15):. PubMed ID: 34361615
[TBL] [Abstract][Full Text] [Related]
24. Palbociclib: A Novel Cyclin-Dependent Kinase Inhibitor for Hormone Receptor-Positive Advanced Breast Cancer.
Mangini NS; Wesolowski R; Ramaswamy B; Lustberg MB; Berger MJ
Ann Pharmacother; 2015 Nov; 49(11):1252-60. PubMed ID: 26324355
[TBL] [Abstract][Full Text] [Related]
25. Palbociclib:CDK4/6 inhibition in the treatment of ER-positive breast cancer.
Owsley J; Jimeno A; Diamond JR
Drugs Today (Barc); 2016 Feb; 52(2):119-29. PubMed ID: 27092341
[TBL] [Abstract][Full Text] [Related]
26. Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance.
Chen P; Lee NV; Hu W; Xu M; Ferre RA; Lam H; Bergqvist S; Solowiej J; Diehl W; He YA; Yu X; Nagata A; VanArsdale T; Murray BW
Mol Cancer Ther; 2016 Oct; 15(10):2273-2281. PubMed ID: 27496135
[TBL] [Abstract][Full Text] [Related]
27. Cyclin-dependent kinase inhibition: an opportunity to target protein-protein interactions.
Klein MA
Adv Protein Chem Struct Biol; 2020; 121():115-141. PubMed ID: 32312419
[TBL] [Abstract][Full Text] [Related]
28. Molecular Pathways: Targeting the Cyclin D-CDK4/6 Axis for Cancer Treatment.
VanArsdale T; Boshoff C; Arndt KT; Abraham RT
Clin Cancer Res; 2015 Jul; 21(13):2905-10. PubMed ID: 25941111
[TBL] [Abstract][Full Text] [Related]
29. Recent advances of highly selective CDK4/6 inhibitors in breast cancer.
Xu H; Yu S; Liu Q; Yuan X; Mani S; Pestell RG; Wu K
J Hematol Oncol; 2017 Apr; 10(1):97. PubMed ID: 28438180
[TBL] [Abstract][Full Text] [Related]
30. Mechanisms of therapeutic CDK4/6 inhibition in breast cancer.
Scott SC; Lee SS; Abraham J
Semin Oncol; 2017 Dec; 44(6):385-394. PubMed ID: 29935900
[TBL] [Abstract][Full Text] [Related]
31. Palbociclib (Ibrance) for metastatic breast cancer.
Med Lett Drugs Ther; 2015 Aug; 57(1475):115-6. PubMed ID: 26262882
[No Abstract] [Full Text] [Related]
32. Targeting breast cancer with CDK inhibitors.
Mayer EL
Curr Oncol Rep; 2015; 17(5):443. PubMed ID: 25716100
[TBL] [Abstract][Full Text] [Related]
33. Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: Recent advances (2015-2019).
Sánchez-Martínez C; Lallena MJ; Sanfeliciano SG; de Dios A
Bioorg Med Chem Lett; 2019 Oct; 29(20):126637. PubMed ID: 31477350
[TBL] [Abstract][Full Text] [Related]
34. Palbociclib-The First of a New Class of Cell Cycle Inhibitors.
Schmidt M; Sebastian M
Recent Results Cancer Res; 2018; 211():153-175. PubMed ID: 30069766
[TBL] [Abstract][Full Text] [Related]
35. New Insights into CDK Regulators: Novel Opportunities for Cancer Therapy.
Bury M; Le Calvé B; Ferbeyre G; Blank V; Lessard F
Trends Cell Biol; 2021 May; 31(5):331-344. PubMed ID: 33676803
[TBL] [Abstract][Full Text] [Related]
36. Cyclin-dependent kinase 4/6 inhibitors in hormone receptor-positive early breast cancer: preliminary results and ongoing studies.
Kwapisz D
Breast Cancer; 2018 Sep; 25(5):506-516. PubMed ID: 29700711
[TBL] [Abstract][Full Text] [Related]
37. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
Roskoski R
Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
[TBL] [Abstract][Full Text] [Related]
38. Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy.
Roberts PJ; Bisi JE; Strum JC; Combest AJ; Darr DB; Usary JE; Zamboni WC; Wong KK; Perou CM; Sharpless NE
J Natl Cancer Inst; 2012 Mar; 104(6):476-87. PubMed ID: 22302033
[TBL] [Abstract][Full Text] [Related]
39. Targeting oncogenic Raf protein-serine/threonine kinases in human cancers.
Roskoski R
Pharmacol Res; 2018 Sep; 135():239-258. PubMed ID: 30118796
[TBL] [Abstract][Full Text] [Related]
40. The potential role of PD0332991 (Palbociclib) in the treatment of multiple myeloma.
Altenburg JD; Farag SS
Expert Opin Investig Drugs; 2015 Feb; 24(2):261-71. PubMed ID: 25494820
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
